S1B-509 / S1 Biopharma - LARVOL DELTA

One-Year Study of S1B-509 vs Placebo for Weight Loss (clinicaltrials.gov) - P2 | N=210 | Not yet recruiting | Sponsor: S1 Biopharma, Inc. | N=150 ➔ 210

Enrollment change • Genetic Disorders • Obesity

One-Year Study of S1B-509 vs Placebo for Weight Loss (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: S1 Biopharma, Inc. | Trial completion date: Dec 2026 ➔ Dec 2027 | Initiation date: Jan 2025 ➔ Oct 2025 | Trial primary completion date: Dec 2025 ➔ Jun 2027

Trial completion date • Trial initiation date • Trial primary completion date • Genetic Disorders • Obesity

One-Year Study of S1B-509 vs Placebo for Weight Loss (clinicaltrials.gov) - P2 | N=150 | Not yet recruiting | Sponsor: S1 Biopharma, Inc.

New P2 trial • Genetic Disorders • Obesity